(2E,2'E)-3,3'-(1,4-Phenylene)bis(1-(benzo[d][1,3]dioxol-5-yl)-prop-2-en-1-one)

ID: ALA3238337

Chembl Id: CHEMBL3238337

PubChem CID: 90671755

Max Phase: Preclinical

Molecular Formula: C26H18O6

Molecular Weight: 426.42

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(/C=C/c1ccc(/C=C/C(=O)c2ccc3c(c2)OCO3)cc1)c1ccc2c(c1)OCO2

Standard InChI:  InChI=1S/C26H18O6/c27-21(19-7-11-23-25(13-19)31-15-29-23)9-5-17-1-2-18(4-3-17)6-10-22(28)20-8-12-24-26(14-20)32-16-30-24/h1-14H,15-16H2/b9-5+,10-6+

Standard InChI Key:  GPZRMFBTKLITBY-NXZHAISVSA-N

Alternative Forms

1. Parent:

   

   ALA3238337

   (E)-1-(1,3-benzodioxol-5-yl)-3-[4-[(E)-3-(1,3-benzodioxol-5-yl)-3-oxoprop-1-enyl]phenyl]prop-2-en-1-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 426.42

Molecular Weight (Monoisotopic): 426.1103

AlogP: 4.94

#Rotatable Bonds: 6

Polar Surface Area: 71.06

Molecular Species:

HBA: 6

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 5.05

CX LogD: 5.05

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.41

Np Likeness Score: 0.03

References

1. Winter E, Devantier Neuenfeldt P, Chiaradia-Delatorre LD, Gauthier C, Yunes RA, Nunes RJ, Creczynski-Pasa TB, Di Pietro A..  (2014)  Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.,  57  (7): [PMID:24611893] [10.1021/jm401879z]

2. Khwaja S, Fatima K, Hasanain M, Behera C, Kour A, Singh A, Luqman S, Sarkar J, Chanda D, Shanker K, Gupta AK, Mondhe DM, Negi AS..  (2018)  Antiproliferative efficacy of curcumin mimics through microtubule destabilization.,  151  [PMID:29605808] [10.1016/j.ejmech.2018.03.063]

3. Haider K, Haider MR, Neha K, Yar MS..  (2020)  Free radical scavengers: An overview on heterocyclic advances and medicinal prospects.,  204  [PMID:32721784] [10.1016/j.ejmech.2020.112607]

Source

Source(1):

• Scientific Literature